Результаты поиска

Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis.

The phase 3 A.R.R.O.W. study demonstrated that treatment with once-weekly carfilzomib (70 mg/m2) and dexamethasone (once-weekly Kd70 mg/m2) improved progression-free survival compared with twice-weekly carfilzomib (27 mg/m2) and dexamethasone (twice-weekly Kd27 mg/m2) in patients with relapsed and refractory multiple myeloma (RRMM; median, 11.2 versus 7.6 months; hazard ratio [HR] = 0.69; 95% confidence interval, 0.54-0.88; P = 0.0029). Once-weekly dosing also improved response rates and depth of response. We performed a subgroup analysis from A.R.R.O.W. according to age (2, once-weekly Kd70 m

Совпадение в полном тексте источника
… In randomized trials, carfilzomib- and daratumumab-based triplets have improved PFS, ORR, and/or OS in relapsed and/or refractory MM patients relative to doublet therapies; however, triplet therapies were also associated with higher rates of toxicity in these studies 17 , 18 , 43 – 46 . … Therefore, patients with lower tolerance for increased toxicity, higher comorbidity burden, and/or frail status may not be suited for triplet therapies 42 . …

Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond.

Despite the challenges imposed by the COVID-19 pandemic, exciting therapeutic progress continues to be made in MM. New drug approvals for relapsed/refractory (RR)MM in 2020/2021 include the second CD38 monoclonal antibody, isatuximab, the first BCMA-targeting therapy and first-in-class antibody-drug conjugate (ADC) belantamab mafodotin, the first BCMA-targeting CAR T cell product Idecabtagen-Vicleucel (bb2121, Ide-Cel), the first in-class XPO-1 inhibitor selinexor, as well as the first-in-class anti-tumor peptide-drug conjugate, melflufen. The present introductory article of the Special Issue

Совпадение в полном тексте источника
… Nevertheless, selinexor may represent an excellent option for all oral triplet therapies. Moreover, selinexor-based triplets may be considered as a strategy to bridge to CAR T cell therapy or for RRMM patients who are not eligible to CAR T cell-, BiTE-, or ADC-therapy. … Phase III trials which compare different triplets would be necessary to determine whether selinexor-containing triplets may be preferred, at least in subgroups of RRMM patients. The lipophilic alkylant melflufen is the first anti-tumor peptide-drug conjugate. …

Evolution of real-world frontline treatment patterns in multiple myeloma.

AbstractThe number of Food and Drug Administration-approved treatments for multiple myeloma (MM), the second most common hematologic malignant neoplasm, has increased substantially over the past 2 decades. Treatment decisions have become more complex over time, and there is variable adoption of new agents in clinical practice. Survival trends have improved with novel therapies; however, these trends are not equitably distributed across patient populations. Although randomized clinical trials have guide treatment strategies, their exclusion of older, medically complex, and socioeconomically dis

Ретроспективный анализ эффективности и безопасности комбинированного ixazomib, lenalidomide и дексаметазона в реанимированном/охотничьем миеломе: опыт северной Италии.

ВВЕДЕНИЕ: Ixazomib, lenalidomide и dexametasone (IRd) были утверждены для лечения повторной/хребетной множественной миеломы (RRMMM) на основе результатов TOURMALINE-MM1. ЦЕЛИ И МЕТОДЫ: Мы провели ретроспективный анализ 106 Пациенты IRM (п) лечатся с помощью IRD 21 - центры в Северной Италии с целью оценки эффективности и безопасности IRd в реальной жизни.Результаты: при инициировании IRD, 34% Доля ПТ в возрасте ≥75 (медленно) 72.5), 8.5% :: имели статус результативности работы ЭКОГ; ≥2, 54.7% [del17p и/или t]4;14) и/или t(14;16) и/или 1 g прибыль/ и], 60.2% были получены ≥2 :: предыдущая терап

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up.

This follow-up extension of a randomised phase II study assessed differences in long-term outcomes between bortezomib-thalidomide-dexamethasone (VTD) and VTD-cyclophosphamide (VTDC) induction therapy in multiple myeloma. Newly diagnosed patients (n = 98) were randomised 1:1 to intravenous bortezomib (1·3 mg/m(2); days 1, 4, 8, 11), thalidomide (100 mg; days 1-21), and dexamethasone (40 mg; days 1-4, 9-12), with/without cyclophosphamide (400 mg/m(2); days 1, 8), for four 21-day cycles before stem-cell mobilisation/transplantation. After a median follow-up of 64·8 months, median time-to-next the

Расовые различия в миеломе и доступ к трансплантации стволовых клеток.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study.

Ixazomib (IXA) is an oral proteasome inhibitor (PI) used in combination with lenalidomide and dexamethasone (IXA-Rd) for patients with relapsed and/or refractory multiple myeloma (RRMM). The REMIX study is one of the largest prospective, real-world analysis of the effectiveness of IXA-Rd in the setting of RRMM. Conducted in France between August 2017 and October 2019, the REMIX study, a non-interventional prospective study, included 376 patients receiving IXA-Rd in second line or later and followed for at least 24 months. Primary endpoint was the median progression-free survival (mPFS). Median

Ixazomib-Lenalidomide-Dexamethasone for the Treatment of Replaped/ Refractory Multieloma: Венгерский анализ реального мира.

Справочная информация/задачи: Несмотря на терапевтические достижения, решение проблем, связанных с рецидивированием/изъятием множественных миеломы (RRMM), по-прежнему сопряжено с трудностями. Для пациентов со слабой, комординируемой, ограниченной мобильностью или в тех случаях, когда предпочтение лечения и доступность лекарств являются ключевыми факторами, всеоральный режим ixazomib-lenalidomide-dexamethasone (IRd) предлагает практическую альтернативу. Методы: Мы провели многоцентральное ретроспективное исследование пациентов RRMM, лечившихся IRd в Венгрии 1 Январь 2020 и 30 Июнь 2025. Результ

Совпадение в полном тексте источника
… As anti-CD38-based triplets and quadruplets continue to move into the frontline setting, many patients worldwide will still require well-tolerated second-line options, and our data provide helpful guidance for such decision-making. … Comparative effectiveness of lenalidomide/dexamethasone-based triplet regimens for treatment of relapsed and/or refractory multiple myeloma in the United States: An analysis of real-world electronic health records data Curr. Probl. …

Оптимизация многочисленных методов лечения миэломы в условиях ограниченности ресурсов: нынешние перспективы и проблемы.

Множественная миелома (ММ) представляет собой серьезную глобальную проблему в области здравоохранения, и за последние десятилетия уровень ее распространенности и смертности неуклонно возрастал. В настоящем обзоре содержится критический анализ нынешнего положения дел в области управления ММ с особым упором на ограниченные ресурсами условия, в которых наиболее заметны различия в диагностических возможностях и вариантах лечения. Комплексный поиск литературы был проведен с использованием многочисленных баз данных, включая рецензированные статьи, клинические руководящие принципы и резюме конференци

Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial.

The optimal way to use immunomodulatory drugs as components of induction and maintenance therapy for multiple myeloma is unresolved. We addressed this question in a large phase III randomized trial, Myeloma XI. Patients with newly diagnosed multiple myeloma (n = 2042) were randomized to induction therapy with cyclophosphamide, thalidomide, and dexamethasone (CTD) or cyclophosphamide, lenalidomide, and dexamethasone (CRD). Additional intensification therapy with cyclophosphamide, bortezomib and dexamethasone (CVD) was administered before ASCT to patients with a suboptimal response to induction

High-dose chemotherapy followed by autologous stem cell transplant for multiple myeloma: Predictors of long-term outcome.

Background & objectivesSurvival of patients with multiple myeloma (MM) has improved in the past two decades following use of novel agents and autologous stem cell transplantation. To determine predictors of long-term outcome, data of MM patients who underwent autologous stem cell transplantation (ASCT) at a tertiary care centre in north India were retrospectively analyzed.MethodsBetween 1995 and 2016, 349 MM patients underwent ASCT. Patients' median age was 52 yr, ranging from 29 to 68 yr, 68.2 per cent were males. Thirty three per cent patients had international staging system (ISS) Stage III

Совпадение в полном тексте источника
… Among novel agents, there was no significant difference in the response rate between those who received doublet (n=178) versus triplet (n=73) (CR 68.8 vs. 71.2%, P=0.223). … Post-transplant CR rate was not significantly different between doublet versus triplet regimen. At present, it is recommended to use triplet (three-drug combinations) 2 , 13 ; however, there is no direct comparison between different triplets being used currently (VTD vs. VRD vs. VCD). …

Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10).

The antiretroviral agent nelfinavir has antimyeloma activity and can overcome resistance to bortezomib. Our phase I/II trial investigated whether adding nelfinavir to lenalidomide-dexamethasone can overcome lenalidomide resistance in lenalidomide-refractory multiple myeloma (MM). Twenty-nine patients were included (high-risk cytogenetic aberrations 31%; ≥2 prior therapy lines 93%; lenalidomide-bortezomib double-refractory 34%). Twenty-four patients (83%) had prior bortezomib and 10 (34%) were lenalidomide-bortezomib double-refractory. They received four cycles of nelfinavir 2500 mg/day with st

Совпадение в полном тексте источника
… Such patients were excluded from drug approval trials evaluating triplets of ixazomib, daratumumab, or carfilzomib in combination with lenalidomide/dexamethasone. … Pomalidomide-based triplets (Elotuzumab + Pom/Dex, Daratumumab + Pom/Dex) have recently been explored and appear to have a similar or better response profile than the Nelfinavir + Len/Dex regimen investigated here 26 , 27 . …

Monoclonal Antibodies in Relapsed-Refractory Multiple Myeloma.

Multiple myeloma is a malignant hematological tumor characterized by the proliferation of clonal plasma cells in the bone marrow causing organ damage. Despite improved survival rates due to the increasing availability of therapeutic options in recent decades, it remains an incurable disease, with most patients ultimately relapsing. Consequently, relapsed/refractory multiple myeloma disease (RRMM) has become a treatment priority. Immunotherapy is the backbone of treatment in RRMM, starting with monoclonal antibodies such as elotuzumab, daratumumab, and isatuximab. The aim of this review is summ

Сочетание результатов ММРГ GA и гематопоэтической оценки в целях оптимизации оценки динамической химиотерапии в множестве миелом.

Терпимость к химотерапии фона существенно влияет на эффективность лечения и выживаемость многих миэломы (ММ), особенно у слабых пациентов. Для оценки степени слабости широко используется Международная рабочая группа по гериатрической оценке миеломы (МРГГ), однако ограничения сохраняются. Динамические и комплексные подходы к оценке могут улучшить стратификацию рисков и способствовать индивидуализированному лечению. 111 Лечение вновь диагностированных пациентов ММ в третьей родственной больнице Университета Сан-Ят-сен (Ян) 2018-Jun 2024). МРГЗ ГА и Гематопоэтический счет (ГС) оценивались на осно

From Time-Limited Therapy to Treatment-Free Observation: The Evolving Role of MRD in CLL Management.

The integration of measurable residual disease (MRD) into the management of chronic lymphocytic leukemia (CLL) has emerged as a major advance in risk stratification and trial design, particularly in the context of time-limited, targeted regimens. High-sensitivity MRD assessment, enabled by multicolor flow cytometry, allele-specific oligonucleotide PCR, and next-generation sequencing (NGS), provides a robust, quantifiable measure for depth of remission and long-term outcomes. Landmark trials-including CLL14, MURANO, CAPTIVATE, and GLOW-have consistently demonstrated that achieving undetectable

Последние новости и достижения в области диагностики и управления клетками Плазмы.

Плазменные клеточные дискразии (ПХД) охватывают разнородную группу расстройств, начиная от асимптоматических свойств-прекурсоров, таких, как моноклональная гаммопатия неопределенного значения (MGUS) и заморозка множественной миеломы (SMM) и кончая открытой множественной миеломой (MM), первичной плазменной лейкемией и системным амилоидозом. Этот обзор основан на структурированном поиске литературы, опубликованной между PubMed, Scopus, Cochrane Bibrary и Web of Science. 2015 и 2025, дополненные референцной проверкой и основными международными руководящими принципами в отношении миэломы для обесп

Совпадение в полном тексте источника
… A major practice evolution has been the move from triplets to quadruplet induction. … The standard therapeutic pathway for transplant-eligible patients involves triplet induction therapy, high-dose melphalan with ASCT, followed by consolidation and maintenance, tailored to disease risk and treatment response (Figure 3 ). …

Frailty in clinical drug trials: Frailty assessments, subgroup analyses and outcomes.

With population ageing, drug trials are increasingly turning their attention to including older, frailer people. This review aimed to provide an overview of how frailty was assessed in published studies related to clinical pharmacological trials, and on the interaction of frailty on the efficacy of the treatments. We searched MEDLINE, EMBASE and Cochrane for clinical drug trials in older people. A total of 4031 abstracts were screened and 17 relevant studies were included in this review. We summarized the findings of these 17 trials into five main clinical areas: cardiovascular (eight studies)

Targeting degradation of IKZF1 and IKZF3 through modulation of the E3 ligase substrates in the context of cellular therapies for multiple myeloma.

Multiple myeloma (MM) is a blood cancer characterized by the clonal evolution of plasma cells. In 2022, there were an estimated 118 000 MM cases and 121 000 deaths worldwide. The treatment landscape of MM has undergone a dramatic transformation in recent decades, shifting from conventional chemotherapy to more targeted approaches. In order to overcome intrinsic and acquired resistance mechanisms that frequently restrict the efficacy of single-agent therapies, drug combination strategies have been developed to simultaneously target multiple pathogenetic pathways. Building on the success of immu

Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety.

Despite the introduction of immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and, more recently, monoclonal antibodies (mAbs), in the chemotherapy regimens for newly diagnosed (NDMM) and relapsed/refractory MM (RRMM), the occurrence of drug resistance remains a challenge in MM patients. This is mainly in the advanced stage of the disease when treatments are limited, and the prognosis is abysmal. Nevertheless, novel molecules and therapeutic approaches are rapidly moving through the several phases of drug development and could address the need for new treatment options. The recent i

Управление пациентами с недавно поставленным диагнозом множественной миеломы, имеющими право на аутологическую трансплантацию стволовых клеток: заявление о позиции Медицинской и научной консультативной группы Австралии по миеломе.

Выживание вновь диагностированных пациентов с множественной миеломой значительно улучшилось в прошлом. 20 годы со значительными терапевтическими достижениями. Несмотря на это, высокодозированная химиотерапия, за которой следует аутологическая трансплантация стволовых клеток, по-прежнему является стандартом ухода за вновь поставленными диагнозами пациентами, которые считаются имеющими право на трансплантацию. Здесь мы резюмируем рекомендации Медицинской и научной консультативной группы Австралии для пациентов, считающихся подходящими для высокодозированной химиотерапии и аутологической транспла